Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ivabradine

- PMLiVE

AstraZeneca’s Tezspire receives EC approval as severe asthma add-on treatment

Tezspire demonstrated superiority across every primary and key secondary endpoint compared to placebo

- PMLiVE

Amgen announces positive results for Lumakras colorectal cancer combination treatment

Results demonstrated a confirmed objective response rate of 30% and median progression free survival of 5.7 months

- PMLiVE

Amgen’s Lumakras shows promising results for patients with non-small cell lung cancer

Results from the phase 3 trial demonstrated superiority over standard of care Docetaxel chemotherapy in KRAS G12C-mutated non-small cell lung cancer

- PMLiVE

AstraZeneca’s Farxiga data shows ‘significant’ mortality benefits in heart failure patients

The pre-specified pooled analysis from two phase 3 trials demonstrated a reduction in cardiovascular death by 14%

- PMLiVE

Amgen announces positive results for Solaris biosimilar for paroxysmal nocturnal haemoglobinuria

ABP 959 demonstrated no ‘clinically meaningful’ difference to the reference product in the phase 3 study

- PMLiVE

Amgen to acquire ChemoCentryx in $3.7bn cash deal

The agreement includes the acquisition of ChemoCentryx’s autoimmune disease treatment Tavneos

- PMLiVE

Amgen’s Riabni combination granted FDA approval for rheumatoid arthritis

Rheumatoid arthritis is a long-term condition that causes painful swelling and stiffness in the joints

- PMLiVE

Amgen’s biosimilar delivers impressive phase 3 results for psoriasis compared to Janssen’s Stelara

The biosimilar was seen to have no clinically meaningful differences to Stelara

- PMLiVE

Amgen and UCB’s Evenity recommended by NICE for severe osteoporosis

In the UK, almost four million people are affected by osteoporosis, resulting in around 520,000 fragility fractures each year

- PMLiVE

Amgen shares new Otezla data at American Academy of Dermatology congress 2022

Around 125 million people worldwide have psoriasis, including an estimated 14 million people in Europe

- PMLiVE

NICE recommends Amgen’s Lumykras for non-small-cell lung cancer

Lung cancer is recorded as being the third most common cancer, with an estimated 48,000 new cases diagnosed in the UK every year

- PMLiVE

Amgen’s Lumakras shows promising results for patients with advanced pancreatic cancer

The results from the phase 1/2 trial showed encouraging and clinically meaningful anticancer activity in patients with the KRAS G12C-mutation

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links